Boston Scientific (NYSE:BSX - Get Free Report)'s stock had its "buy" rating reissued by Needham & Company LLC in a report released on Friday,Benzinga reports. They currently have a $121.00 price target on the medical equipment provider's stock. Needham & Company LLC's price target would indicate a potential upside of 23.11% from the company's current price.
Other equities analysts also recently issued reports about the stock. Royal Bank Of Canada reissued an "outperform" rating on shares of Boston Scientific in a research note on Thursday, July 24th. Truist Financial increased their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research note on Thursday, July 24th. Citigroup reissued a "buy" rating and issued a $125.00 price target (up from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Finally, Oppenheimer raised shares of Boston Scientific from a "market perform" rating to an "outperform" rating and increased their price target for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $118.04.
View Our Latest Research Report on Boston Scientific
Boston Scientific Stock Performance
Shares of NYSE:BSX opened at $98.29 on Friday. The company has a market cap of $145.64 billion, a price-to-earnings ratio of 58.51, a price-to-earnings-growth ratio of 2.37 and a beta of 0.65. The company has a 50-day moving average price of $104.51 and a 200-day moving average price of $102.15. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific has a 12 month low of $80.64 and a 12 month high of $109.50.
Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company's quarterly revenue was up 22.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities analysts anticipate that Boston Scientific will post 2.85 EPS for the current year.
Insider Buying and Selling at Boston Scientific
In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the sale, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock worth $18,397,457 in the last ninety days. 0.50% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the business. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in Boston Scientific by 72.9% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 344 shares of the medical equipment provider's stock worth $37,000 after buying an additional 145 shares during the period. Valeo Financial Advisors LLC boosted its stake in shares of Boston Scientific by 4.3% in the second quarter. Valeo Financial Advisors LLC now owns 22,551 shares of the medical equipment provider's stock worth $2,422,000 after acquiring an additional 930 shares during the period. Osaic Holdings Inc. boosted its stake in shares of Boston Scientific by 20.0% in the second quarter. Osaic Holdings Inc. now owns 144,745 shares of the medical equipment provider's stock worth $15,459,000 after acquiring an additional 24,080 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Boston Scientific by 44.1% during the second quarter. China Universal Asset Management Co. Ltd. now owns 26,576 shares of the medical equipment provider's stock worth $2,855,000 after purchasing an additional 8,139 shares in the last quarter. Finally, Orion Porfolio Solutions LLC lifted its holdings in Boston Scientific by 9.5% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 36,550 shares of the medical equipment provider's stock worth $3,926,000 after purchasing an additional 3,165 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.
About Boston Scientific
(
Get Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
